News

"We selected Theradex to assist the Company in pursuing our proposed studies in Hodgkin’s Lymphoma because of Theradex’s invaluable assistance in finalizing our prior IND with the FDA

As part of the collaboration, Kangstem Biotech will provide iNSCs to ORIG3N for use in its disease-modeling platform. Kangstem Biotech has developed a novel approach to generating patient-specific

This UCART19 clinical trial is sponsored by Servier in close collaboration with Pfizer. The pediatric Phase I is an open label, non-comparative, monocenter study to evaluate the safety

The growth, which represents a compound annual growth rate of 13.6%, will take place in the US, France, Germany, Italy, Spain, the UK, and Japan, the seven major

The company secured orphan drug designation from the US Food and Drug Administration for Epidiolex (cannabidiol or CBD) to treat IS. A two-part pivotal Phase 3 study is

The agreement is in connection with the divestiture process mandated by the US Federal Trade Commission (FTC) in relation toTeva’s $40.5bn acquisition of Allergan’s generic drugs portfolio. Impax

Under the double-blind, double-dummy, parallel group FULFIL study, 1,810 patients were randomized to receive either GSK’s fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or budesonide/formoterol. The study met its objectives, with the

Over 300 employees, investors and company partners attended the unveiling of the 43,500-square-foot, state-of-the-art plant. The facility has been designed to produce chimeric antigen receptor (CAR) and T-cell

Adaptimmune previously received orphan drug destination from the U.S. Food and Drug Administration for its NY-ESO SPEAR T-cell therapy in this indication. "While unresectable or metastatic soft tissue